Miranova

Method of action: Contraceptive, Endocrine Therapy, Estrogen-Progestational, Sex Hormones And Modulators Of The Genital System

Treatment option: Hormonal Contraceptives, Venous Thromboembolism, Birth Control, Thromboembolism

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Miranova

Quick Facts

Property	Description
Active ingredients	Ethinyl Estradiol and Levonorgestrel
Form	Oral Tablet (monophasic)
Pharmacological class	Combined Oral Contraceptive (COC)
Common use	Prevention of pregnancy
Origin	Synthetic hormones

What Type of Medication is Miranova?

Miranova is a prescription-only pharmaceutical preparation officially classified as a Combined Oral Contraceptive (COC). This oral medication is fundamentally indicated for pregnancy prevention in women of reproductive potential. As a combined medicine, it is designated as an oral contraceptive. This classification signifies that the tablet contains two distinct synthetic hormones, an estrogen and a progestin, which work together to achieve systemic contraception.

This low-dose COC is clinically recognized for providing high efficacy when used consistently, which has established it as a standard method for reliable birth control. This approach is distinct from progestin-only pills, which utilize a singular hormone and are generally positioned for specific patient groups who must avoid estrogen.

Composition and Differentiation

The active components in Miranova are the synthetic hormones Ethinyl Estradiol (EE) and Levonorgestrel (LNG), which are the internationally recognized nonproprietary names (INN) for these substances. Ethinyl Estradiol acts as the synthetic estrogen component, while Levonorgestrel is the synthetic progestin derived from the norpregnane group, a combination widely studied in contraception. This combination is used for contraceptive purposes, primarily by preventing or delaying ovulation.

Miranova is produced as an Oral Tablet and is defined as a monophasic formulation. This means that unlike some other COCs (which may be bi- or tri-phasic), every active tablet delivers a consistent, fixed dose of both hormones across the entire active cycle, simplifying the hormonal regimen. This specific combination is frequently found in low-dose COCs, a modern feature designed to optimize efficacy while minimizing hormonal burden compared to older, higher-dose pills.

Regulatory References

What side effects are possible with Miranova?

Possible Side Effects and Safety Information

The official safety documentation for Miranova, an oral contraceptive containing levonorgestrel and ethinyl estradiol, organizes potential adverse events into categories based on frequency and clinical significance.

Serious Adverse Reactions

Regulatory documents emphasize the risk of rare but serious vascular thromboembolic events, which are a class-wide documented risk for combined oral contraceptives. These include the potential for deep vein thrombosis, pulmonary embolism, myocardial infarction (heart attack), and stroke. These events represent the highest-risk profile components.

Other serious events officially noted in regulatory trial data have included nephrolithiasis (kidney stones), cholecystitis, and the development of malignant melanoma.

Commonly Reported Adverse Events

The most frequent adverse events, which are typically less serious, are officially documented as:

Irregular bleeding or spotting between expected periods. Regulatory data notes this incidence is highest in the initial cycle and decreases significantly over the first few months of use.
Headache and migraine
Nausea
Breast tenderness or pain
Weight changes

Safety Restrictions and Population Considerations

Use of this medication is officially contraindicated in women with a history of or existing risk factors for serious thromboembolic disorders or certain liver tumors. Furthermore, the risk of serious cardiovascular events is documented to increase with age (especially ge 35 years) and cigarette smoking, leading to official restrictions against use in women over 35 who smoke. Official notes require discontinuation if a serious adverse event, such as a thrombotic event or significant hepatic dysfunction, is suspected or confirmed.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory documentation for combined oral contraceptives containing Ethinyl Estradiol and Levonorgestrel defines the overdose profile as generally having low acute toxicity, meaning the ingestion of an excessive number of tablets is typically not associated with serious or life-threatening outcomes. The documented presentations are primarily linked to the hormonal content and include nausea, vomiting, and withdrawal bleeding (vaginal bleeding) in females.

Required Emergency Actions

Official prescribing information mandates that individuals seek immediate medical help in all suspected overdose situations. Emergency services should be contacted right away if the person who has overdosed exhibits severe manifestations, such as loss of consciousness or difficulty breathing. This action is required to ensure continuous monitoring of vital signs and symptom progression.

Management and Considerations

No specific antidote is known for this combination of active ingredients. Therefore, management procedures described in regulatory resources focus on providing symptomatic and supportive treatment. In extreme circumstances, the administration of activated charcoal may be considered by medical personnel. For the pediatric population, official resources note that symptoms of overdose are often limited to minor effects such as nausea, vomiting, or minor vaginal bleeding.

Therapeutic Uses of Miranova

Miranova, a Combined Oral Contraceptive (COC), plays a role in managing symptoms in addition to its primary function in pregnancy prevention. Combined oral contraceptives are often utilized to help with various health conditions, particularly menstrual-related disorders. The medication is relevant in contexts involving episodic or fluctuating manifestations, helping to ease the overall burden of distressing manifestations.

Miranova is generally used to help address menstrual cycle irregularities, Dysmenorrhea (painful periods), Menorrhagia (abnormally heavy menstrual bleeding), and symptoms linked to androgen activity such as hormonal acne. It is applied in clinical settings that involve acute or unstable symptom patterns.

Summary: Symptomatic Support

Domain	Supportive Benefit
Gynaecological Symptoms	Relevant for easing symptoms that interfere with daily functioning.
Cycle Consistency	Supports long-term symptomatic management and control.
Androgen-related Symptoms	Contributes to easing the overall symptom burden related to hormonal skin changes.

Reliable Birth Control and Symptomatic Support

Miranova's primary benefit supports long-term pregnancy prevention. Beyond contraception, its use helps address groups of symptoms that may become intense or disruptive. The therapeutic support assists with maintaining functional stability and helps maintain a sense of stability when symptoms are more noticeable.

Regulatory References

NIH StatPearls overview of Oral Contraceptive Pills

Eligibility and Restrictions for Use

Miranova, a Combined Oral Contraceptive (COC), is officially indicated for use by females of reproductive potential to prevent pregnancy. Eligibility is strictly defined by regulatory guidelines, primarily due to the risk of serious cardiovascular events associated with COCs.

Absolute Contraindications (Must Not Use)

Miranova is contraindicated and must not be used by individuals with a history of or current venous or arterial thrombotic diseases (e.g., deep vein thrombosis, stroke, heart attack, or inherited hypercoagulopathies). Use is also prohibited in women over age 35 who smoke.

Non-eligibility also extends to women with: current or history of breast cancer or other hormone-sensitive cancers; certain liver tumors or severe liver disease; uncontrolled hypertension; or undiagnosed abnormal uterine bleeding.

Restricted and Conditional Use

Pregnancy and Lactation: The medication is contraindicated if pregnancy is known or suspected and is not recommended for use by nursing mothers.
Postpartum: Initiation should be delayed until at least four weeks after delivery in non-breastfeeding women.
Surgery: Use must be stopped at least four weeks before and through two weeks after major surgery or prolonged immobilization.
Age: The product is not indicated for use in postmenopausal women.

What should I know about interactions with other medicines?

Miranova’s official interaction profile, as defined by regulatory authorities, governs specific constraints with other medicinal products.

Formal Interaction Restrictions

Formal contraindicated combinations include Hepatitis C drug regimens containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the documented risk of significant liver enzyme (ALT) elevations. Additionally, co-administration with oral Tranexamic Acid is prohibited because of a heightened pharmacodynamic risk of thromboembolism.

Exposure-Altering Interactions

Clinically significant interactions involve medicines that affect hormone metabolism. Metabolic enzyme inducers, such as certain antiepileptic drugs (e.g., phenytoin, rifampin) and the herbal product St. John's wort, may decrease the plasma concentrations of both contraceptive hormones. This reduction in exposure can result in diminished contraceptive effectiveness. Official documentation requires the use of a backup non-hormonal contraceptive method when enzyme inducers are co-administered, which must continue for 28 days after the inducer is discontinued.

A dose separation rule applies to the bile acid sequestrant Colesevelam, which can decrease the systemic exposure of the Ethinyl Estradiol component and must be administered 4 or more hours apart from the oral contraceptive. Internally, the Ethinyl Estradiol component increases the concentration of Levonorgestrel by affecting its clearance via Sex Hormone Binding Globulin (SHBG) synthesis.

Mechanism of Action

The mechanism of action for Miranova, a combined hormonal preparation, is based on three primary, concurrent physiological effects created by the synthetic hormones Ethinyl Estradiol (EE) and Levonorgestrel (LNG).

Central Suppression of the Reproductive Axis

This mechanism involves the synergistic action of both hormones acting as agonists at the Estrogen and Progesterone Receptors. This creates a powerful negative feedback signal that suppresses the central Hypothalamic-Pituitary-Ovarian (HPO) axis . The suppression directly inhibits the release of FSH (Follicle-Stimulating Hormone) and blocks the pre-ovulatory LH surge (Luteinizing Hormone), which results in the core physiological change of anovulation (cessation of egg release).

Localized Tissue Alteration and Functional Effects

Levonorgestrel acts on peripheral tissues to produce two auxiliary physiological effects. It modifies the structure of the cervical mucus, significantly increasing its viscosity, which alters the transport dynamics of sperm into the upper genital tract. Concurrently, the hormonal action induces structural changes in the endometrium (uterine lining), reducing the tissue's morphological receptivity to blastocyst attachment.

Pharmacodynamic Stabilization

Ethinyl Estradiol reinforces central HPO suppression and acts on the liver to induce the synthesis of Sex Hormone-Binding Globulin (SHBG). This increased SHBG level modulates the systemic availability of Levonorgestrel, maintaining the plasma hormone levels required to support the central and peripheral mechanistic actions across the cycle.

Dosage and Administration Information

Miranova (Ethinyl Estradiol and Levonorgestrel) is a combined oral contraceptive (COC) for oral administration in a standardized 28-day regimen. This medicine is typically used for continuous, long-term use and is taken daily at the same time every day to maintain consistent hormone levels and uphold the planned use pattern.

The standard regimen involves taking one tablet daily for 28 consecutive days. This cycle is structurally composed of 21 active tablets containing the fixed hormone dose, followed by 7 inactive (placebo) tablets. This pattern is crucial, as the tablets must be taken in the sequence indicated on the packaging. The tablets may be taken without regard to food.

Initiation of use involves specific procedures: use may begin on the first day of menstruation (Day 1 Start) or on the first Sunday following menstruation (Sunday Start). The product is not indicated for use in postmenopausal or geriatric populations.

For all users, specific detailed protocols exist for handling missed active tablets, which depend on the number of tablets missed and the timing within the cycle. This fixed, cyclic protocol ensures the structured use of the medicine across all treatment courses, which begins following the completion of the previous 28-day pack.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Miranova

Miranova, which contains the synthetic hormones Ethinyl Estradiol and Levonorgestrel, was evaluated in clinical research to understand its use in pregnancy prevention and research has explored whether this combination may influence certain menstrual symptoms. The available evidence comes primarily from randomized controlled trials (RCTs) and long-term observational studies applied in studies examining patient-reported experiences in women of reproductive potential.

Evidence for Use in Pregnancy Prevention

Research for the Combined Oral Contraceptive (COC) class, including this specific combination, was studied for its use in pregnancy prevention. The main data are derived from large-scale, multi-center trials that track outcomes over roughly one year. These studies research examined contraceptive utility, which is typically quantified by the Pearl Index (PI)—a metric that calculates the number of unintended pregnancies that occur per 100 women using the method for a year.

This combination was associated with patterns related to the incidence of pregnancies measured in controlled settings. The results apply only to the populations studied. Real-world utility may differ because clinical trials primarily measure "perfect use" (consistent, correct taking of the pill), while typical use can be affected by missed doses.

Evidence for Symptom Management

Miranova was evaluated in clinical trials and observational settings. Research examined short-term symptom changes and outcomes related to physical discomfort, such as painful periods (dysmenorrhea), heavy bleeding (menorrhagia), and hormonal acne. Findings describe patterns observed in studies where participants reported changes in the severity of menstrual pain and alterations in bleeding patterns.

Overall, the data show patterns related to cycle regularity, but evidence is limited regarding the precise comparative impact of this exact low-dose Levonorgestrel formulation against other formulations studied for these symptoms. Furthermore, findings were mixed in trials that focused on more complex mood symptoms related to premenstrual dysphoric disorder (PMDD) across different continuous dosing regimens.

Key Studies & References NIH StatPearls: Oral Contraceptive Pills (Detailed Overview)

Frequently Asked Questions (FAQ)

Common questions about Miranova (FAQ)

Q: Is it safe to drink alcohol while taking Miranova?

A: Official product information does not impose restrictions on alcohol intake. Clinical data and regulatory documents generally do not list alcohol as a formal drug interaction with combined oral contraceptives. However, heavy or excessive alcohol use could potentially affect hormone levels or increase common side effects of the pill, like headaches or nausea.

Q: Does Miranova protect against STIs?

A: No, Miranova is a prescription medicine intended only for the prevention of pregnancy. According to the official product information for combined oral contraceptives, this medication does not protect against HIV/AIDS or any other sexually transmitted infections (STIs). Patients who require protection against STIs must use an appropriate barrier method, such as a condom.

Q: What should I do if I forget to take my placebo pill?

A: If you forget to take one or more of the placebo (inactive) pills, it is generally advised to discard them, as they contain no active hormones. Missing inactive pills does not affect contraceptive protection. The recommendation is to begin the next pack of Miranova on the scheduled day, adhering to the pattern on the packaging.

Q: What are the signs of a serious allergic reaction to Miranova?

A: Serious allergic reactions, while rare, are noted in the official regulatory information for this type of medication. Signs may include a severe rash, hives (urticaria), or swelling of the face, lips, or tongue (angioedema). If a serious allergic reaction is suspected, official guidance strongly advises seeking immediate medical assistance.

How should Miranova be stored and disposed of?

Storage and Handling Requirements

Miranova must be stored at controlled room temperature, typically maintained between 20 C to 25 C (68 F to 77 F), with permitted temperature excursions up to 30 C. Official labeling requires the medication to be kept in its original container to protect it from both light and moisture. To prevent accidental ingestion, the product must always be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Miranova must be handled as pharmaceutical waste and disposed of according to local guidelines. The official guidance from regulatory bodies recommends utilizing a drug take-back program whenever possible. If a take-back program is unavailable, the tablets should not be flushed down the toilet, but instead, mixed with an unpalatable substance and sealed in a bag for disposal in household trash, following specific regulatory procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.